Phase 3 (105 companies)
Companies with at least one active program at Phase 3.
| Ticker | Company | Therapeutic areas | Phase 3 programs | Lead stage | Mkt cap | Programs |
|---|---|---|---|---|---|---|
| FDMT | 4D Molecular Therapeutics | OphthalmologyRespiratory Rare | 2 | Phase 3 | $677M | 5 |
| AARD | Aardvark Therapeutics | DermatologyMetabolic+1 Rare | 1 | Phase 3 | $25.6M | 3 |
| ABVX | Abivax | Immunology | 1 | Phase 3 | $7.50B | 2 |
| ACIU | AC Immune | Neurology Rare | 1 | Phase 3 | $222M | 11 |
| ALDX | Aldeyra Therapeutics | DermatologyOncology+1 | 2 | NDA Submitted | $38.3M | 5 |
| ALT | Altimmune | GI/HepatologyMetabolic+1 | 1 | Phase 3 | $405M | 3 |
| AMLX | Amylyx Pharmaceuticals | MetabolicNeurology Rare | 1 | Phase 3 | $3.79B | 5 |
| ANAB | AnaptysBio | DermatologyGI/Hepatology+2 Rare | 2 | Approved | $1.39B | 9 |
| ANNX | Annexon | HematologyNeurology+2 Rare | 2 | Phase 3 | $796M | 6 |
| RCUS | Arcus Biosciences | DermatologyImmunology+1 | 3 | Phase 3 | $2.63B | 8 |
| ARDX | Ardelyx | GI/HepatologyRenal | 1 | Approved | $724M | 4 |
| AXSM | Axsome Therapeutics | Neurology Rare | 6 | Approved | $6.96B | 15 |
| BLTE | Belite Bio | MetabolicOphthalmology Rare | 1 | NDA Submitted | $6.21B | 6 |
| BCRX | Biocryst Pharmaceuticals | DermatologyImmunology+1 Rare | 1 | Approved | $1.98B | 4 |
| BCTX | BriaCell Therapeutics | Oncology | 1 | Phase 3 | $34.5M | 8 |
| CADL | Candel Therapeutics | Oncology | 2 | Phase 3 | $670M | 4 |
| CRDL | Cardiol Therapeutics | Cardiovascular Rare | 1 | Phase 3 | $121M | 4 |
| RNAC | Cartesian Therapeutics | ImmunologyNeurology+1 Rare | 1 | Phase 3 | $230M | 4 |
| CLDX | Celldex Therapeutics | DermatologyImmunology+1 | 4 | Phase 3 | $2.35B | 9 |
| CGEN | Compugen | Oncology | 4 | Phase 3 | $186M | 7 |
| CRVS | Corvus Pharmaceuticals | DermatologyOncology+1 Rare | 1 | Phase 3 | $889M | 7 |
| CRNX | Crinetics Pharmaceuticals | MetabolicOncology Rare | 2 | Approved | — | 6 |
| DFTX | Definium Therapeutics | Neurology | 2 | Phase 3 | $4.47B | 4 |
| IRON | Disc Medicine | GI/HepatologyHematology+2 Rare | 2 | Phase 3 | $3.59B | 9 |
| DYN | Dyne Therapeutics | MetabolicNeurology Rare | 1 | NDA Submitted | $3.39B | 10 |
| EXEL | Exelixis | CardiovascularOncology | 3 | Approved | $17.0B | 23 |
| EYPT | EyePoint | Ophthalmology | 1 | Phase 3 | $31.0M | 2 |
| FBIO | Fortress Biotech | DermatologyHematology+3 Rare | 2 | Approved | $61.7M | 12 |
| GUTS | Fractyl Health | Metabolic | 1 | Phase 3 | — | 1 |
| GNLX | Genelux | Oncology | 1 | Phase 3 | $88.7M | 3 |
| GERN | Geron | Oncology | 1 | Approved | $638M | 3 |
| GOSS | Gossamer Bio | Cardiovascular Rare | 1 | NDA Submitted | — | 4 |
| GLSI | Greenwich LifeSciences | Oncology | 1 | Phase 3 | $223M | 1 |
| HRMY | Harmony Biosciences | MetabolicNeurology Rare | 4 | Approved | $1.94B | 17 |
| HROW | Harrow | Ophthalmology Rare | 2 | Approved | $1.01B | 15 |
| HELP | Helus Pharma | Neurology | 1 | Phase 3 | $655M | 3 |
| IDYA | IDEAYA Biosciences | Oncology | 1 | NDA Submitted | $3.02B | 14 |
| IMTX | Immatics | Oncology | 1 | Phase 3 | $968M | 8 |
| IMRX | Immuneering | Oncology | 1 | Phase 3 | $238M | 5 |
| IMUX | Immunic | GI/HepatologyNeurology | 1 | Phase 3 | $106M | 4 |
| IMCR | Immunocore | DermatologyInfectious Disease+2 | 3 | Approved | $1.60B | 15 |
| IMVT | Immunovant | ImmunologyNeurology Rare | 1 | Phase 3 | $6.31B | 5 |
| INMB | Inmune Bio | Dermatology Rare | 1 | Phase 3 | $35.0M | 1 |
| INSM | Insmed | CardiovascularImmunology+3 Rare | 2 | Approved | $25.1B | 15 |
| NTLA | Intellia Therapeutics | CardiovascularImmunology Rare | 2 | NDA Submitted | $1.59B | 3 |
| IVVD | Invivyd | Infectious Disease | 1 | Approved | $166M | 5 |
| IONS | Ionis Pharmaceuticals | CardiovascularHematology+5 Rare | 12 | Approved | $6.55B | 29 |
| KROS | Keros Therapeutics | NeurologyOncology Rare | 2 | Phase 3 | $184M | 5 |
| KPRX | Kiora Pharmaceuticals | Ophthalmology Rare | 1 | Phase 3 | $6.4M | 4 |
| KOD | Kodiak Sciences | Ophthalmology | 6 | Phase 3 | $6.24B | 8 |
| KYTX | Kyverna Therapeutics | ImmunologyNeurology+1 Rare | 1 | NDA Submitted | $302M | 7 |
| LBRX | LB Pharmaceuticals | Neurology | 1 | Phase 3 | $1.36B | 3 |
| LQDA | Liquidia | CardiovascularImmunology+1 Rare | 2 | Approved | $3.97B | 9 |
| MAIA | MAIA Biotechnology | Oncology | 1 | Phase 3 | $64.5M | 7 |
| MGTX | MeiraGTx | ImmunologyMetabolic+2 Rare | 1 | Phase 3 | $864M | 16 |
| MESO | Mesoblast | CardiovascularGI/Hepatology+2 Rare | 2 | Approved | $1.85B | 5 |
| MIST | Milestone Pharmaceuticals | Cardiovascular | 1 | Approved | $95.0M | 2 |
| MLTX | MoonLake Immunotherapeutics | DermatologyImmunology Rare | 1 | NDA Submitted | $981M | 4 |
| NKTR | Nektar Therapeutics | DermatologyImmunology+2 | 1 | Phase 3 | $1.27B | 11 |
| NGEN | NervGen Pharma | Neurology | 1 | Phase 3 | $143M | 3 |
| NGNE | Neurogene | Neurology Rare | 1 | Phase 3 | $506M | 1 |
| NAMS | NewAmsterdam Pharma | CardiovascularMetabolic+1 | 2 | NDA Submitted | $2.27B | 6 |
| NRIX | Nurix Therapeutics | ImmunologyNeurology+1 | 2 | Phase 3 | $1.67B | 13 |
| NVCT | Nuvectis Pharma | HematologyOncology+1 Rare | 2 | Phase 3 | $719M | 9 |
| OCGN | Ocugen | Infectious DiseaseOphthalmology Rare | 4 | Phase 3 | $314M | 12 |
| OCS | Oculis Holding | NeurologyOphthalmology Rare | 1 | Phase 3 | $417M | 5 |
| OLMA | Olema Pharmaceuticals | Oncology | 1 | Phase 3 | $641M | 3 |
| IRD | Opus Genetics | Ophthalmology Rare | 2 | Approved | $348M | 12 |
| ORIC | Oric Pharmaceuticals | Oncology | 1 | Phase 3 | $914M | 5 |
| OTLK | Outlook Therapeutics | Ophthalmology | 2 | Approved | $106M | 3 |
| PTN | Palatin Technologies | ImmunologyMetabolic+1 Rare | 1 | Phase 3 | $11.2M | 8 |
| PTGX | Protagonist Therapeutics | DermatologyHematology+2 Rare | 3 | Approved | $8.62B | 12 |
| RAPP | Rapport Therapeutics | Neurology | 1 | Phase 3 | $1.45B | 10 |
| RLAY | Relay Therapeutics | DermatologyOncology Rare | 1 | Approved | $4.11B | 4 |
| RVPH | Reviva Pharmaceuticals | CardiovascularDermatology+2 Rare | 1 | Phase 3 | $4.8M | 10 |
| RVMD | Revolution Medicines | Oncology | 4 | Approved | $41.6B | 11 |
| RYTM | Rhythm Pharmaceuticals | Metabolic Rare | 5 | Approved | $7.78B | 14 |
| SGMT | Sagimet Biosciences | DermatologyMetabolic | 1 | Phase 3 | $698M | 3 |
| SRPT | Sarepta Therapeutics | NeurologyRespiratory Rare | 1 | Approved | $1.91B | 11 |
| SLS | SELLAS Life Sciences Group | Oncology | 1 | Phase 3 | $1.70B | 9 |
| SLDB | Solid Biosciences | CardiovascularNeurology Rare | 1 | Phase 3 | $736M | 6 |
| STOK | Stoke Therapeutics | Neurology Rare | 1 | Phase 3 | $1.74B | 2 |
| GPCR | Structure Therapeutics | MetabolicRespiratory Rare | 2 | Phase 3 | $4.35B | 5 |
| SMMT | Summit Therapeutics | Oncology | 3 | NDA Submitted | $13.1B | 6 |
| TSHA | Taysha Gene Therapies | Neurology Rare | 1 | Phase 3 | $1.41B | 4 |
| TLX | Telix Pharmaceuticals | Oncology | 4 | Approved | $3.27B | 25 |
| TENX | Tenax Therapeutics | Cardiovascular Rare | 1 | Phase 3 | $77.0M | 2 |
| TGTX | Tg Therapeutics | Neurology Rare | 1 | Approved | $9.16B | 6 |
| TVTX | Travere Therapeutics | MetabolicRenal Rare | 1 | Approved | $4.76B | 7 |
| HURA | TuHURA Biosciences | Oncology | 1 | Phase 3 | $104M | 4 |
| RARE | Ultragenyx Pharmaceutical | CardiovascularMetabolic+1 Rare | 2 | Approved | $1.57B | 10 |
| VNDA | Vanda Pharmaceuticals | CardiovascularDermatology+6 Rare | 8 | Approved | $231M | 27 |
| PCVX | Vaxcyte | Infectious Disease | 2 | Phase 3 | $10.1B | 7 |
| VRCA | Verrica Pharmaceuticals | DermatologyOncology | 1 | Approved | $54.8M | 3 |
| VKTX | Viking Therapeutics | MetabolicNeurology Rare | 2 | Phase 3 | $3.42B | 9 |
| VIR | Vir Biotechnology | Infectious DiseaseOncology Rare | 1 | Phase 3 | $2.09B | 12 |
| VRDN | Viridian Therapeutics | ImmunologyOphthalmology | 1 | Approved | $3.24B | 7 |
| VOR | Vor Biopharma | ImmunologyNeurology Rare | 2 | Phase 3 | $1.22B | 2 |
| VTVT | vTv Therapeutics | HematologyMetabolic+1 Rare | 1 | Phase 3 | $84.4M | 9 |
| XFOR | X4 Pharmaceuticals | — | 1 | Approved | $325M | 2 |
| XNCR | Xencor | ImmunologyNeurology+1 Rare | 1 | Approved | $2.68B | 28 |
| XENE | Xenon Pharmaceuticals | Neurology Rare | 3 | NDA Submitted | $3.79B | 9 |
| ZBIO | Zenas BioPharma | DermatologyImmunology+2 Rare | 2 | NDA Submitted | $1.92B | 11 |
| ZNTL | Zentalis Pharmaceuticals | Oncology | 1 | Phase 3 | $123M | 1 |
| ZYME | Zymeworks | OncologyRespiratory | 1 | Approved | $2.10B | 11 |
No companies match.